IPO Timeline
Broker Results (T-2)
2021-04-27
Some brokers release in afternoon
Grey Market (T-1)
2021-04-28
Afternoon
HKEX Allotment (T-1)
2021-04-28
Evening
Registrar Allotment (T-1)
2021-04-28
Evening
Listing Day (T)
2021-04-29
First day of trading
Company Overview
| Stock Name | 兆科眼科有限公司 - B |
|---|---|
| Stock Code | 06622 |
| Company Full Name | 兆科眼科有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事研究、開發及商業化眼科藥物。 |
| Listing Date | 2021-04-29 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣東省廣州市南沙區珠江工業園美德三路1號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.zkoph.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 16.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 20.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 830,373,600 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 14.32 |
|---|---|
| First Day Open | HK$ 15.52 |
| First Day Change | -14.76% |
| First Day Volume | 41422900.0 |
| First Day Turnover | 620468000.0 |
Use of Proceeds
| Use of Proceeds | 1、約621.3百萬港元（占所得款項凈額的32.0%）將用于我們截至最后實際可行日期由25種候選藥物組成的龐大管線中兩種核心產品的臨床開發及商業化； 2、約893.1百萬港元（占所得款項凈額的46.0%）將用于為我們的其他在研候選藥物的持續研發活動及商業化提供資金； 3、約135.9百萬港元（占所得款項凈額的7.0%）將用于我們位于南沙的先進生產設施進行生產線擴張，以籌備未來年度的產品上市； 4、約97.1百萬港元（占所得款項凈額的5.0%）將用于為我們的業務開發活動及在研藥物的擴展提供資金； 5、約194.2百萬港元（占所得款項凈額的10.0%）將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
富瑞金融集团香港有限公司 CE ATS546
Overall Coordinators (4)
高盛（亚洲）有限责任公司 CE ACC536
富瑞金融集团香港有限公司 CE ATS546
海通国际证券有限公司 CE AAF806
香港上海汇丰银行有限公司
Joint Bookrunners (8)
高盛（亚洲）有限责任公司 CE ACC536
富瑞金融集团香港有限公司 CE ATS546
海通国际证券有限公司 CE AAF806
香港上海汇丰银行有限公司
复星国际证券有限公司 CE AAF432
麦格理资本股份有限公司 CE AAC534
浦银国际融资有限公司 CE BFZ375
VMS Securities Limited CE AAC621
Joint Lead Managers (8)
高盛（亚洲）有限责任公司 CE ACC536
富瑞金融集团香港有限公司 CE ATS546
海通国际证券有限公司 CE AAF806
香港上海汇丰银行有限公司
复星国际证券有限公司 CE AAF432
麦格理资本股份有限公司 CE AAC534
浦银国际融资有限公司 CE BFZ375
VMS Securities Limited CE AAC621
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | CaaS Capital Master Fund LP | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 2 | GIC Private Limited | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 3 | Golden Valley Global Limited | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 4 | Jennison Associates LLC | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 5 | Mass Ave Global, Inc. | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 6 | Matthews Asia Funds | 116,667,600 HKD | — | 5.62% | — | 6 months | 2021-10-29 |
| 7 | OrbiMed Funds | 38,883,600 HKD | — | 1.87% | — | 6 months | 2021-10-29 |
| 8 | VMS Zhaoke Investment Fund SP | 77,775,600 HKD | — | 3.75% | — | 6 months | 2021-10-29 |
Directors & Management
| Chairman | 李小羿 |
|---|---|
| Company Secretary | 邱淑欣 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李氏大藥廠控股有限公司(25.9%);新加坡政府投資有限公司(12.99%);VMS Holdings Limited(6.6%);Panacea Venture Healthcare Fund GP I, L.P(6.15%);高瓴資本管理有限公司(5.65%);TPG Asia VII SF Pte. Ltd.(5.65%) |
|---|
IPO Timeline
